^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    EP300 (E1A binding protein p300)

    i
    Other names: EP300, E1A binding protein p300, p300, KAT3B, RSTS2
    8d
    Enhancing Oncolytic Adenovirus Replication by Early Region 1A Protein-Mediated Degradation of E1A Binding Protein p300. (PubMed, MedComm (2020))
    In this study, OAd can reduce p300 expression by promoting its ubiquitination via E1A, thereby enhancing viral replication and cell cytotoxicity. Therefore, this study can provide a biomarker for screening patients who are sensitive to OAd and new ideas for clinical tumor treatment.
    Journal
    |
    EP300 (E1A binding protein p300) • STING (stimulator of interferon response cGAMP interactor 1) • IFI16 (Interferon Gamma Inducible Protein 16) • IFNB1 (Interferon Beta 1)
    9d
    EP300/NCOA1 complex drives glioma angiogenesis via H3K27 acetylation-dependent activation of VEGFA. (PubMed, Exp Cell Res)
    Co-immunoprecipitation and nuclear-cytoplasmic assays confirmed that EP300 forms a nuclear transcriptional co-activator complex with NCOA1, which stabilizes its nuclear localization and synergistically enhances VEGFA expression. Together, these findings identify EP300 as a central epigenetic regulator of glioma angiogenesis and highlight the EP300/NCOA1-VEGFA axis as a potential therapeutic target.
    Journal
    |
    VEGFA (Vascular endothelial growth factor A) • EP300 (E1A binding protein p300) • NCOA1 (Nuclear Receptor Coactivator 1)
    22d
    WDHD1 promotes hepatocellular carcinoma progression by affecting the cell cycle and immune evasion. (PubMed, Transl Oncol)
    Additionally, high WDHD1 levels were associated with increased CD4 memory T cell infiltration, elevated tumor mutational burden (TMB), and enhanced expression of key immune checkpoint markers, suggesting a potential for improved response to immunotherapy in these patients. These findings suggest WDHD1 as a novel oncogenic driver and promising therapeutic target in HCC.
    Journal • Tumor mutational burden • IO biomarker
    |
    TMB (Tumor Mutational Burden) • CREBBP (CREB binding protein) • CD4 (CD4 Molecule) • EP300 (E1A binding protein p300) • MIR139 (MicroRNA 139) • CDC45 (Cell Division Cycle 45) • MIR22 (MicroRNA 22)
    26d
    Computational Analysis of Differentially Expressed Circulating MicroRNA and Identification of Key Genes in Prostate Cancer. (PubMed, Indian J Clin Biochem)
    To conclude and for future research, 8 miRNAs are yet to be explored for non-invasive potential as diagnostic and prognostic biomarkers in Prostate cancer progression and development. The target genes of each miRNA could provide novel insights in developing therapeutics for better management of disease.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • PTEN (Phosphatase and tensin homolog) • FGFR1 (Fibroblast growth factor receptor 1) • CCND1 (Cyclin D1) • PIK3R1 (Phosphoinositide-3-Kinase Regulatory Subunit 1) • EP300 (E1A binding protein p300) • MAPK1 (Mitogen-activated protein kinase 1) • CDKN1A (Cyclin-dependent kinase inhibitor 1A) • CREB5 (CAMP Responsive Element Binding Protein 5) • E2F1 (E2F transcription factor 1)
    1m
    DLD, upregulated by YY1, fuels glioblastoma multiforme progression via EphA2 phosphorylation to activate PI3K/AKT/mTOR. (PubMed, QJM)
    DLD functions as an oncogene in GBM and represents a potential biomarker and therapeutic target.
    Journal
    |
    EP300 (E1A binding protein p300) • DLD (Dihydrolipoamide Dehydrogenase) • YY1 (YY1 Transcription Factor) • CRNDE (Colorectal Neoplasia Differentially Expressed)
    1m
    Epigenetic Regulation of MicroRNA Expression by Hepatitis B Virus Pre-S2 Mutant Promotes Hepatocellular Carcinoma Tumorigenesis. (PubMed, Liver Int)
    Collectively, this study provided new mechanistic insights and therapeutic perspectives for pre-S2 mutant-associated HCC tumorigenesis.
    Journal
    |
    EP300 (E1A binding protein p300)
    1m
    Epigenetic maintenance of the injury response state in glioblastoma stem cells. (PubMed, Neurooncol Adv)
    Functional studies demonstrated that this loss of state identity coincides with decreased self-renewal and invasion in GSCs and delayed tumor initiation and progression in a mouse GBM model. Collectively, our results establish EP300 as a key regulator of IR state identity in GSCs and provide a mechanistic basis for therapeutic targeting of aggressive cellular states in GBM.
    Journal
    |
    CD44 (CD44 Molecule) • EP300 (E1A binding protein p300)
    2ms
    Elucidating key targets and mechanisms of diethyl phthalate-induced colorectal cancer through network toxicology and molecular docking. (PubMed, PLoS One)
    This study provides a theoretical framework for exploring the molecular mechanisms through which DEP may contribute to CRC development, emphasizing the value of network toxicology in cancer research. These findings may inform future investigations into the risks of DEP exposure and support public health policy and the development of targeted therapeutic strategies.
    Journal
    |
    EP300 (E1A binding protein p300) • HDAC2 (Histone deacetylase 2) • TGFB1 (Transforming Growth Factor Beta 1) • HDAC1 (Histone Deacetylase 1)
    2ms
    Anti-inflammatory activity and potential anti-inflammatory mechanisms of Artemisia scoparia essential oil. (PubMed, J Pharm Pharmacol)
    These findings suggest that ASEO has great potential as a natural anti-inflammatory agent, its key compositions and multiple anti-inflammatory mechanisms make it a promising candidate for further research and development for clinical applications.
    Journal
    |
    ER (Estrogen receptor) • TNFA (Tumor Necrosis Factor-Alpha) • EP300 (E1A binding protein p300) • PTGS2 (Prostaglandin-Endoperoxide Synthase 2) • PPARG (Peroxisome Proliferator Activated Receptor Gamma) • MPO (Myeloperoxidase) • PACERR (PTGS2 Antisense NFKB1 Complex-Mediated Expression Regulator RNA) • PPARA (Peroxisome Proliferator Activated Receptor Alpha)
    |
    dexamethasone
    2ms
    Chronic lymphocytic leukemia with IGH/BCL2 fusion and clonal heterogeneity: phenotypic and molecular profiling analysis of a rare case. (PubMed, Ann Hematol)
    NGS revealed that a common progenitor cell with BCL2-IgH translocation and mutations in TP53, KMT2A, KMT2C, and KMT2D gave rise to two distinct subclones: one (CD5 + CD23+CD200+) CLL driven by mutations in TNFAIP3 and BCORL1, and the other (CD5-CD23-CD200-) driven by mutations in EP300, NOTCH1, and BCL2. This case highlights the significance of clonal heterogeneity in CLL and underscores the crucial role of MFC, flow sorting, and molecular genetics in diagnosing and understanding the complex evolution of this disease.
    Journal • IO biomarker
    |
    TP53 (Tumor protein P53) • BCL2 (B-cell CLL/lymphoma 2) • NOTCH1 (Notch 1) • KMT2A (Lysine Methyltransferase 2A) • IGH (Immunoglobulin Heavy Locus) • KMT2D (Lysine Methyltransferase 2D) • KMT2C (Lysine Methyltransferase 2C) • EP300 (E1A binding protein p300) • TNFAIP3 (TNF Alpha Induced Protein 3) • CD5 (CD5 Molecule) • CD200 (CD200 Molecule) • BCORL1 (BCL6 Corepressor Like 1) • FCER2 (Fc Fragment Of IgE Receptor II)
    |
    TP53 mutation • IGH mutation • MLL mutation
    2ms
    BAF complex-independent gene activation by SS18::SSX. (PubMed, bioRxiv)
    Our work reveals new therapeutic vulnerabilities in synovial sarcoma and suggests broader relevance for targeting coactivator-dependent transcription in fusion-driven cancers. BAF degradation does not alter SS18::SSX-activated transcriptional programsDirect SS18::SSX transcriptional activation is independent of BAF interactionThe SS18 C-terminus engages the co-activator EP300 to promote gene expressionSmall molecule degraders of EP300/CREBBP abolish SS18::SSX-mediated transcription.
    Journal
    |
    SMARCA4 (SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily A, member 4) • CREBBP (CREB binding protein) • EP300 (E1A binding protein p300) • SS18 (SS18 Subunit Of BAF Chromatin Remodeling Complex)